These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 25804827)

  • 21. [State of the art treatment of progressive or refractory multiple myeloma].
    Schmidt-Wolf IG; Straka C; Scheid C; Einsele H; Goldschmidt H; Engelhardt M
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2091-5. PubMed ID: 25268212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
    Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibodies in multiple myeloma: data from the 2015 ASH meeting.
    Lonial S
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):82-4. PubMed ID: 27057804
    [No Abstract]   [Full Text] [Related]  

  • 24. Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma.
    Hutchinson AT; Jones DR; Raison RL
    Mol Immunol; 2015 Oct; 67(2 Pt A):89-94. PubMed ID: 25964097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
    Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
    Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
    [No Abstract]   [Full Text] [Related]  

  • 26. Carfilzomib-associated tumor lysis syndrome.
    Shely RN; Ratliff PD
    Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibodies in hematologic malignancies: clinical status. Highlights from the American Society of Hematology 42nd annual meeting. December 1-5, 2000, San Francisco, California, USA. Abstracts.
    Oncology (Williston Park); 2001 Mar; 15(3 Suppl 4):7-48. PubMed ID: 11357830
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting.
    Terpos E; Ntanasis-Stathopoulos I;
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):499-508. PubMed ID: 32376237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety of daratumumab for the treatment of multiple myeloma.
    Cejalvo MJ; Ribas P; de la Rubia J
    Expert Opin Drug Saf; 2017 Jun; 16(6):753-760. PubMed ID: 28490215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab.
    Liang S; Feng W; Ma H; Zhang L; Jia C
    Hematology; 2022 Dec; 27(1):332-336. PubMed ID: 35255237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The American Society of Hematology--46th Annual Meeting and Exposition. Drug highlights I.
    Evans L
    IDrugs; 2005 Jan; 8(1):7-9. PubMed ID: 15650932
    [No Abstract]   [Full Text] [Related]  

  • 33. American Society of Hematology--47th Annual Meeting and Exposition. Multiple myeloma and anti-idiotype vaccines.
    Murch L
    IDrugs; 2006 Feb; 9(2):87-9. PubMed ID: 16523393
    [No Abstract]   [Full Text] [Related]  

  • 34. The American Society of Hematology--46th Annual Meeting and Exposition. Drug highlights II.
    Evans L
    IDrugs; 2005 Jan; 8(1):10-3. PubMed ID: 15650933
    [No Abstract]   [Full Text] [Related]  

  • 35. Multiple myeloma, immunotherapy and minimal residual disease.
    Kusenda J; Kovarikova A
    Neoplasma; 2016; 63(5):651-8. PubMed ID: 27468868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
    Jakubowiak AJ
    Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highlights in the treatment of chronic lymphocytic leukemia from the 2013 meeting of the American Society of Hematology.
    Molica S
    Expert Rev Hematol; 2014 Apr; 7(2):187-90. PubMed ID: 24617332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. American Society of Hematology--51st annual meeting & exposition. Part 2.
    Shumoogam J; Beecher N
    IDrugs; 2010 Feb; 13(2):60-2. PubMed ID: 20127550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
    de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
    J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.